1. In vivo Prevalence of Alzheimer Biomarkers in Dementia with Lewy Bodies.
- Author
-
Paraskevas, George P., Bougea, Anastasia, Constantinides, Vasilios C., Bourbouli, Mara, Petropoulou, Olga, and Kapaki, Elisabeth
- Subjects
- *
DIAGNOSIS of dementia , *AGE distribution , *ALZHEIMER'S disease , *AMINO acids , *BIOMARKERS , *CONSENSUS (Social sciences) , *CLINICAL pathology , *ENZYME-linked immunosorbent assay , *LEWY body dementia , *NERVE tissue proteins , *PEPTIDES , *SEX distribution , *PSYCHOSOCIAL factors , *EDUCATIONAL attainment , *DISEASE progression , *THREONINE , *IN vivo studies - Abstract
Background: Neuropathological studies indicate concomitant Alzheimer's disease (AD) pathology in patients with dementia with Lewy bodies (DLB). Objectives: To measure cerebrospinal fluid (CSF) levels of β-amyloid peptide with 42 amino acids (Aβ42), total tau protein (τT), and tau phosphorylated at threonine 181 (τP-181) in 38 patients fulfilling the diagnostic criteria of probable DLB according to the most recent (4th consensus) report. Methods: Double-sandwich commercial ELISAs (Innotest; Fujirebio, Gent, Belgium) were used for measurements. Results: According to the current cutoff values of our laboratory, 4 biomarker profiles were noted: abnormal levels of Aβ42 only (44.7%), full AD profile (39.5%), abnormal levels of τT only (5.3%), and normal levels of all 3 biomarkers (10.5%). AD profile was associated with female sex, older age, lower education, and lower MMSE scores. Conclusions: Reduction in Αβ42 in DLB may be more common (>80% of patients) than previously thought, and ∼40% may have the typical CSF AD biomarker profile. AD biochemistry in DLB may be an evolving process showing increasing frequency with disease progression. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF